Halozyme Therapeutics Inc (HALO):企業の財務・戦略的SWOT分析

◆英語タイトル:Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH44899FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Halozyme Therapeutics Inc (HALO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded, recombinant formulation of rHuPH20, which enables administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and also with an enhanced resorption of radiopaque agents in subcutaneous urography. It also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20. The company works in partnership with Pfizer, Roche, Baxalta, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and Argenx for advancing treatment for various cancer types. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc Key Recent Developments

Feb 23,2021: Halozyme reports fourth quarter 2020 results and full year 2020 results
Feb 23,2021: Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
Feb 10,2021: Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
Jan 11,2021: Halozyme provides 2021 financial guidance highlighted by strong revenue and EPS growth
Nov 23,2020: Halozyme raises full year 2020 guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Halozyme Therapeutics Inc – Key Facts
Halozyme Therapeutics Inc – Key Employees
Halozyme Therapeutics Inc – Key Employee Biographies
Halozyme Therapeutics Inc – Major Products and Services
Halozyme Therapeutics Inc – History
Halozyme Therapeutics Inc – Company Statement
Halozyme Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Halozyme Therapeutics Inc – Business Description
Other Break-up: Product Sales, Net
Performance
Other Break-up: Revenue Under Collaborative Agreements
Performance
Other Break-up: Royalties
Performance
Geographical Segment: Belgium
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: The US
Performance
R&D Overview
Halozyme Therapeutics Inc – Corporate Strategy
Halozyme Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Halozyme Therapeutics Inc – Strengths
Halozyme Therapeutics Inc – Weaknesses
Halozyme Therapeutics Inc – Opportunities
Halozyme Therapeutics Inc – Threats
Halozyme Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Halozyme Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 23, 2021: Halozyme reports fourth quarter 2020 results and full year 2020 results
Feb 23, 2021: Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
Feb 10, 2021: Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
Jan 11, 2021: Halozyme provides 2021 financial guidance highlighted by strong revenue and EPS growth
Nov 23, 2020: Halozyme raises full year 2020 guidance
Nov 02, 2020: Halozyme reports third quarter 2020 results and raises full year 2020 guidance
Oct 06, 2020: argenx expands capabilities in antibody engineering through key technology partnerships
Aug 10, 2020: Halozyme reports significant recent achievements and second quarter 2020 results
May 11, 2020: Halozyme reports first quarter 2020 results
Feb 24, 2020: Halozyme announces CFO transition
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Halozyme Therapeutics Inc, Key Facts
Halozyme Therapeutics Inc, Key Employees
Halozyme Therapeutics Inc, Key Employee Biographies
Halozyme Therapeutics Inc, Major Products and Services
Halozyme Therapeutics Inc, History
Halozyme Therapeutics Inc, Subsidiaries
Halozyme Therapeutics Inc, Key Competitors
Halozyme Therapeutics Inc, Ratios based on current share price
Halozyme Therapeutics Inc, Annual Ratios
Halozyme Therapeutics Inc, Annual Ratios (Cont...1)
Halozyme Therapeutics Inc, Annual Ratios (Cont...2)
Halozyme Therapeutics Inc, Interim Ratios
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Halozyme Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Halozyme Therapeutics Inc (HALO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fonterra Co-operative Group Ltd:企業のM&A・事業提携・投資動向
    Fonterra Co-operative Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fonterra Co-operative Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Stentys SA (STNT):医療機器:M&Aディール及び事業提携情報
    Summary Stentys SA (Stentys) is a medical device company that designs, develops and markets self-expanding stents for the treatment of patients with acute myocardial infarction and coronary disease. The company’s products include xposition S self-applying stent, mistent biodegradable sirolimus relea …
  • Bulgarian Energy Holding EAD:企業の戦略的SWOT分析
    Bulgarian Energy Holding EAD - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Omnova Solutions Inc (OMN):企業の財務・戦略的SWOT分析
    Omnova Solutions Inc (OMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • China Communications Services Corporation Ltd (552):企業の財務・戦略的SWOT分析
    China Communications Services Corporation Ltd (552) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s ke …
  • Lea County Electric Cooperative Inc:企業の戦略的SWOT分析
    Lea County Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Asiana Airlines Inc.
    Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report Summary Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Alkermes Plc (ALKS):製薬・医療:M&Aディール及び事業提携情報
    Summary Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspen …
  • Dakota Gasification Co:企業の戦略的SWOT分析
    Dakota Gasification Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Industrial and Commercial Bank of China Ltd:戦略・SWOT・企業財務分析
    Industrial and Commercial Bank of China Ltd - Strategy, SWOT and Corporate Finance Report Summary Industrial and Commercial Bank of China Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Electricidade de Mocambique EP:企業の戦略的SWOT分析
    Electricidade de Mocambique EP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Entercom Communications Corp (ETM):企業の財務・戦略的SWOT分析
    Summary Entercom Communications Corp (Entercom) is a provider of media and entertainment services. The company offers radio broadcasting programs. It owns and operates radio stations in various formats, including classic rocks, sports, news, talk, adult contemporary, alternative and country and othe …
  • ARMZ Uranium Holding Co:企業の戦略的SWOT分析
    ARMZ Uranium Holding Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Shenzhen Century Plaza Hotel Co., Ltd.:企業の戦略・SWOT・財務情報
    Shenzhen Century Plaza Hotel Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shenzhen Century Plaza Hotel Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Kiniksa Pharmaceuticals Ltd (KNSA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kiniksa Pharmaceuticals Ltd (Kiniksa Pharmaceuticals) is a clinical-stage biopharmaceutical company focused on discovery, acquisition, development and commercialization of therapeutic medicines for the treatment of auto inflammatory and autoimmune diseases. Its pipeline product portfolio inc …
  • The Cooper Companies, Inc.:企業の戦略・SWOT・財務情報
    The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Astaldi Spa:企業の戦略・SWOT・財務分析
    Astaldi Spa - Strategy, SWOT and Corporate Finance Report Summary Astaldi Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • BioElectronics Corp (BIEL):企業の財務・戦略的SWOT分析
    BioElectronics Corp (BIEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Pure Technologies Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Pure Technologies Ltd. (Pure Technologies) develops technologies for inspection, monitoring and management of physical infrastructure such as buildings, water and hydrocarbon pipelines, and bridges. It provides proprietary monitoring equipment for pipelines, bridges and structures; technical …
  • Theratechnologies Inc (TH):企業の財務・戦略的SWOT分析
    Theratechnologies Inc (TH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆